Please select


For My Business

< R10m annual turnover

For My Business

> R10m annual turnover

Please select


For My Business

< R10m annual turnover

For My Business

> R10m annual turnover

Switch to FNB Business

Product shop

By Turnover

First Business Zero (R0 - R5 million p.a) Gold Business (R0 - R5 million p.a) Platinum Business (R5 million - R60 million p.a) Enterprise Business (R60 million - R150 million+ p.a)

Transact

Business Accounts Credit Cards Cash Solutions Merchant Services eWallet Pro Staffing Solutions ATM Solutions Ways to bank Fleet Services Guarantees

Savings and Investments

Save and Invest 3PIM (3rd Party Investment Manager)

Borrow

FNB Cash Advance Overdraft Loans Debtor Finance Leveraged Finance Private Equity Securities Based Lending Selective Invoice Discounting Asset Based Finance Alternative Energy Solutions Commercial Property Finance Fleet Services

Insure

Insurance

For my employees

Staffing Solutions Employee benefits

Forex + Trade

Foreign Exchange Imports and exports Structured Trade + Commodity Finance Business Global Account (CFC account)

Value Adds + Rewards

Connect my business the dti initiatives Enterprise and supplier development Business Hub eBucks Rewards for Business DocTrail™ CIPC Integration Channel Instant Accounting Solutions Instant Payroll Instant Cashflow Instant Invoicing SLOW 24/7 Business Desk FNB Business Fundaba nav» Marketplace Prepaid products Accounting integrations

Industry Expertise

Philanthropy Chinese Business Islamic Banking Agriculture Public Sector Education Healthcare Franchise Motor Dealership Tourism

Going Global

Global Commercial Banking

Financial Planning

Overview

Bank Better

KYC / FICA Debit order + recipient switching Electronic Alerts

Corporates + Public Sector

Corporate Public Sector

All savings + investment accounts


Cash deposits

Notice deposits Immediate access Access to a portion Fixed deposits

Share investing

Shares

Tax-free investing

Tax-free accounts

Funds/unit trusts

Ashburton specialised products

Invest abroad

Offshore products

I want to save for

Personal goals Child's education Emergencies Tax-free

Compare similar

Compare

Additional options

Show me all Help me chosse Find an advisor

Financial planning

Overview

Back

Trade Ideas

Global trade idea - UnitedHealth Group Inc. (UNH US) - BUY

 

UnitedHealth Group Inc. is one of the largest and most prominent players in the US healthcare industry. It operates across various facets of healthcare, including insurance, healthcare delivery, data analytics, and pharmacy benefit management, with the goal of improving healthcare access and outcomes for individuals and organisations.

Long term, the group's strong healthcare enrolment numbers, as well as its focus on value-based care, are expected to be key drivers in its pursuit of long-term earnings growth between 13% and 16%. The group is expected to hold its market-share lead in several divisions, with cost efficiencies remaining supportive of the group's services and offerings.

Technically, the price appears to be stable with less volatility and fewer abrupt price swings (see the insert), which makes the stock attractive as an investing option. Stability in the price can make a stock more attractive to conservative or risk-averse investors.

The stock is trading above its 200-day simple moving average (SMA) of $488 and key support levels (see the black trendline on the main chart). A series of green Heikin-Ashi candles also supports the bullish direction.

The start of upside momentum, according to the MACD indicator, and the upwards trajectory of the On-Balance Volume (OBV) indicator, offers further support.

Share Information

Share code UNH
Industry Health Care Equipment & Service
Market Capital (USD) 468.2 billion
One year total return 0.89%
Return year-to-date -3.56%
Current price (USD) 505.45
52 week high (USD) 558.10
52 week low (USD) 445.68
Financial year end December
Closing paragraph While the stock price has been relatively range bound since earlier this year, several technical indicators suggest that the price will break to the upside.

Consensus expectations

(Bloomberg)

FY22 FY23E FY24E FY25E
Headline Earnings per Share (USD) 22.19 24.84 27.87 31.50
Growth (%) 11.96 12.19 13.01
Dividend Per Share (USD) 6.40 7.05 7.77 8.55
Growth (%) 10.19 10.20 10.00
Forward PE (times) 20.34 18.13 16.05
Forward Dividend Yield (%) 1.40 1.54 1.69
Closing paragraph Attractive earnings growth is expected in the short-to-medium term.

Buy/Sell Rationale

Technical Analysis:

  • The lower panel depicts the crossover signals (above the zero-line) generated by the Moving Average Convergence Divergence (MACD) indicator. A bullish crossover above the zero line indicates a shift in momentum from bearish to bullish. It suggests that buying pressure is increasing, and the stock's price may be poised to move higher.
  • Our entry range is between $500 and $520, or as close as possible to the current reference price of $505.45 - a drop below this level may indicate a structural change in the trend, giving reason to negate the idea.
  • Our target price is $560, representing an upside of ~10.8% from current levels. Forward calculations of the RSI suggest that the stock will be in overbought territory at $600, making our profit target realistic.
  • The current RSI reading of 58, compared to readings of 30 for oversold territory and 70 for overbought territory, suggests that there is some room for further upside.
  • Our proposed time to exit is early January 2024, although investors can adjust the time horizon depending on price behaviour.
  • A drop below $490 (~3.1% below current levels) would imply weakening technicals. As such, a stop-loss is recommended at this level.
  • We suggest a medium at-risk allocation for this trade. Increase portfolio exposure for a break above $520.

Long-term fundamental view:

  • The group operates through four reportable segments: UnitedHealthcare (~55% of revenue), OptumRx (~25% of revenue), OptumHealth (~15%), and OptumInsight (~5%).
  • UnitedHealthcare is the core health benefits segment and includes several divisions (Employer & Individual, Medicare & Retirement, Community & State and Global). The next largest division, OptumRx, offers pharmacy care services and programmes.
  • The OptumHealth segment is focused on care delivery, care management, wellness, and consumer engagement, as well as health financial services. The OptumInsight division serves the needs of hospital systems, physicians, health plans, governments, and life sciences companies.
  • Premiums account for about 80% of revenue, while products, services, and investment and other income generate the remaining 20%.
  • Results for 2Q23 were solid, with both top- and bottom-line metrics (revenue: +16%, earnings per share: +10%) surpassing market expectations. The medical-loss ratio of 83.2% was generally in line with expectations.
  • Earnings from operations came in at $8.1 billion, up 13% y/y, with strong contributions from Optum and UnitedHealthcare, even as the company continued to invest to support growth.
  • The group reiterated its confidence in accelerated growth amid encouraging medical trends with an increasing focus on behavioural care patterns, which should continue to be supportive of growth during 2H23.
  • In terms of risks, the group is exposed to the possibility for an accelerated increase in medical costs, which could lead to margin pressure. Further strain in the economic environment may limit premium increases, thus negatively affecting earnings.

Share Name and position CNC - BUY
(Continue to hold)
BTAL - BUY
(Continue to hold)
GS - Stop-loss
(Close the position)
Entry 66.44 19.20 344.57
Current 69.99 20.16 327.89
Movement 5.3% 5% -4.8%
Summary text The stock remains above key support levels and is trading just above its 200-day simple moving average. Upside momentum remains supportive.

Our profit target is $76 with a trailing stop-loss of $66.30. Exit the position on 30 November 2023.
A falling wedge pattern remains of interest. The stock is trading above its 200-day simple moving average, with upside momentum supportive of the trade idea.

Our profit target is $21 with a stop-loss of $19.50. Exit the position on 13 December 2023.
The stock breached our stop-loss level, leading us to close the position.

Share Name and position KO - Stop-loss
(Close the position)
FTNT - Stop-loss
(Close the position)
FOXF - Stop-loss
(Close the position)
Entry 61.64 63.5 105.69
Current 56.53 58.24 96.58
Movement -8.3% -8.3% -8.6%
Summary text The stock breached our stop-loss level, leading us to close the position. The stock breached our stop-loss level, leading us to close the position. The stock breached our stop-loss level, leading us to close the position.

How would you like to log in?